845 related articles for article (PubMed ID: 18991631)
21. Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors.
Gunaherath GM; Marron MT; Wijeratne EM; Whitesell L; Gunatilaka AA
Bioorg Med Chem; 2013 Sep; 21(17):5118-29. PubMed ID: 23859777
[TBL] [Abstract][Full Text] [Related]
22. Synthesis and biological evaluation of coumarin replacements of novobiocin as Hsp90 inhibitors.
Kusuma BR; Khandelwal A; Gu W; Brown D; Liu W; Vielhauer G; Holzbeierlein J; Blagg BS
Bioorg Med Chem; 2014 Feb; 22(4):1441-9. PubMed ID: 24461493
[TBL] [Abstract][Full Text] [Related]
23. Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines.
Burlison JA; Avila C; Vielhauer G; Lubbers DJ; Holzbeierlein J; Blagg BS
J Org Chem; 2008 Mar; 73(6):2130-7. PubMed ID: 18293999
[TBL] [Abstract][Full Text] [Related]
24. Stimulation of the weak ATPase activity of human hsp90 by a client protein.
McLaughlin SH; Smith HW; Jackson SE
J Mol Biol; 2002 Jan; 315(4):787-98. PubMed ID: 11812147
[TBL] [Abstract][Full Text] [Related]
25. Crystal structure of the middle and C-terminal domains of Hsp90α labeled with a coumarin derivative reveals a potential allosteric binding site as a drug target.
Peng S; Woodruff J; Pathak PK; Matts RL; Deng J
Acta Crystallogr D Struct Biol; 2022 May; 78(Pt 5):571-585. PubMed ID: 35503206
[TBL] [Abstract][Full Text] [Related]
26. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
Garg G; Khandelwal A; Blagg BS
Adv Cancer Res; 2016; 129():51-88. PubMed ID: 26916001
[TBL] [Abstract][Full Text] [Related]
27. Revisiting silibinin as a novobiocin-like Hsp90 C-terminal inhibitor: Computational modeling and experimental validation.
Cuyàs E; Verdura S; Micol V; Joven J; Bosch-Barrera J; Encinar JA; Menendez JA
Food Chem Toxicol; 2019 Oct; 132():110645. PubMed ID: 31254591
[TBL] [Abstract][Full Text] [Related]
28. Antibiotic radicicol binds to the N-terminal domain of Hsp90 and shares important biologic activities with geldanamycin.
Schulte TW; Akinaga S; Soga S; Sullivan W; Stensgard B; Toft D; Neckers LM
Cell Stress Chaperones; 1998 Jun; 3(2):100-8. PubMed ID: 9672245
[TBL] [Abstract][Full Text] [Related]
29. In vivo function of Hsp90 is dependent on ATP binding and ATP hydrolysis.
Obermann WM; Sondermann H; Russo AA; Pavletich NP; Hartl FU
J Cell Biol; 1998 Nov; 143(4):901-10. PubMed ID: 9817749
[TBL] [Abstract][Full Text] [Related]
30. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
31. Interaction of radicicol with members of the heat shock protein 90 family of molecular chaperones.
Schulte TW; Akinaga S; Murakata T; Agatsuma T; Sugimoto S; Nakano H; Lee YS; Simen BB; Argon Y; Felts S; Toft DO; Neckers LM; Sharma SV
Mol Endocrinol; 1999 Sep; 13(9):1435-48. PubMed ID: 10478836
[TBL] [Abstract][Full Text] [Related]
32. Development of small molecule Hsp90 inhibitors: utilizing both forward and reverse chemical genomics for drug identification.
Neckers L
Curr Med Chem; 2003 May; 10(9):733-9. PubMed ID: 12678776
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological and genetic analysis of 90-kDa heat shock isoprotein-aryl hydrocarbon receptor complexes.
Cox MB; Miller CA
Mol Pharmacol; 2003 Dec; 64(6):1549-56. PubMed ID: 14645686
[TBL] [Abstract][Full Text] [Related]
34. Alternative approaches to Hsp90 modulation for the treatment of cancer.
Hall JA; Forsberg LK; Blagg BS
Future Med Chem; 2014 Sep; 6(14):1587-605. PubMed ID: 25367392
[TBL] [Abstract][Full Text] [Related]
35. Modulation of Hsf1 activity by novobiocin and geldanamycin.
Conde R; Belak ZR; Nair M; O'Carroll RF; Ovsenek N
Biochem Cell Biol; 2009 Dec; 87(6):845-51. PubMed ID: 19935870
[TBL] [Abstract][Full Text] [Related]
36. A novel chaperone-activity-reducing mechanism of the 90-kDa molecular chaperone HSP90.
Itoh H; Ogura M; Komatsuda A; Wakui H; Miura AB; Tashima Y
Biochem J; 1999 Nov; 343 Pt 3(Pt 3):697-703. PubMed ID: 10527951
[TBL] [Abstract][Full Text] [Related]
37. Alternate strategies of Hsp90 modulation for the treatment of cancer and other diseases.
Brandt GE; Blagg BS
Curr Top Med Chem; 2009; 9(15):1447-61. PubMed ID: 19860731
[TBL] [Abstract][Full Text] [Related]
38. C-terminal modulators of heat shock protein of 90 kDa (HSP90): State of development and modes of action.
Bickel D; Gohlke H
Bioorg Med Chem; 2019 Nov; 27(21):115080. PubMed ID: 31519378
[TBL] [Abstract][Full Text] [Related]
39. The high-resolution crystal structure of a 24-kDa gyrase B fragment from E. coli complexed with one of the most potent coumarin inhibitors, clorobiocin.
Tsai FT; Singh OM; Skarzynski T; Wonacott AJ; Weston S; Tucker A; Pauptit RA; Breeze AL; Poyser JP; O'Brien R; Ladbury JE; Wigley DB
Proteins; 1997 May; 28(1):41-52. PubMed ID: 9144789
[TBL] [Abstract][Full Text] [Related]
40. Novobiocin Analogues That Inhibit the MAPK Pathway.
Hall JA; Seedarala S; Zhao H; Garg G; Ghosh S; Blagg BS
J Med Chem; 2016 Feb; 59(3):925-33. PubMed ID: 26745854
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]